JP MORGAN/CALL/VERTEX PHARMACEUTICALS/405/0.1/17.01.25 | Market Closed - Börse Stuttgart 09:50:50 25/06/2024 BST | ||
| 8.93 EUR | +4.81% |
|
| Current month | +29.99% | ||
| 1 month | +18.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 8.93 | +4.81% |
| 24/06/24 | 8.52 | -2.96% |
| 21/06/24 | 8.78 | +4.40% |
| 20/06/24 | 8.41 | +1.20% |
| 19/06/24 | 8.31 | -6.73% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 09:50 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL1Z9K |
| ISIN | DE000JL1Z9K2 |
| Date issued | 17/04/2023 |
| Strike | 405 $ |
| Maturity | 17/01/2025 (205 Days) |
| Parity | 10 : 1 |
| Emission price | 3.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.84 € |
|---|---|
| Lowest since issue | 3.18 € |
| Spread | 0.3 € |
| Spread % | 3.30% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474
USD
Average target price
465.5
USD
Spread / Average Target
-1.79%
- Stock Market
- Warrants
- Warrant
